Alcoholism and Drug Abuse Boosting Prevalence of Female Sexual Dysfunction Problems


Female Sexual Dysfunction Treatment Market Trends Insights and Forecast Research 2021-2027 | Statistics, Competition Strategies, Business Analysis, Opportunities and Share Demand, Global Size and Future Investment Analysis with Covid-19 Impact

The increasing incidence of chronic diseases such as kidney problems, diabetes, neurological diseases, and others are driving the global sexual dysfunction treatment market predicts Fortune Business Insights in their new study. The study is titled ”Female Sexual Dysfunction Treatment Market”, Size, Share and Global Trend By Type (Arousal Disorder, Penetration Disorder, Female Orgasmic Disorder), By Therapy (Estrogen Therapy, Androgen Therapy, Others), By Age (25 Years, 25-40 Years, Above 40 Years) and Geography Forecast Till 2026.”. This report focusses on major factors restricting and driving the growth of the female sexual dysfunction treatment market during the forecast period, 2018 to 2026.

As per the report, the age group of 40 years and above is dominating the current female sexual dysfunction treatment market and anticipated to continue doing so in the coming years. This is attributable to the wide adoption of unhealthy lifestyle resulting in hormonal imbalance, further leading to sexual dysfunction.

Get Sample PDF Brochure:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/female-sexual-dysfunction-treatment-market-100850

 

New Drug Approvals to Bode Well for Market Players

Companies are focussing on major strategies such as new product launches, company collaborations, and merger and acquisitions for gaining the lion's share in the market. For instance, a new drug application (NDA) of a first-in-class melanocortin-4 receptor called bremelanotide by AMAG Pharmaceuticals was accepted by the Food and Drug Administration (FDA). This drug is meant to treat hypoactive sexual desire disorders (HSDD) among premenopausal women. Such innovations are likely to bode well for the market as well for company portfolio in future.

Some of the companies functioning in the global female sexual dysfunction treatment market are Cipla Inc., Pfizer, Inc., AMAG Pharmaceuticals, Apricus Biosciences, Inc., Merck & Co., Inc., GlaxoSmithKline, plc., and others.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

For more information in the analysis of this report, visit: 

https://www.fortunebusinessinsights.com/industry-reports/female-sexual-dysfunction-treatment-market-100850

Enter with Facebook Login